Baird Medical's AI Tumor Ablation Surgical Robot Wins 'Most Valuable Investment Award,' Pioneering AI and Robotics Integration in Healthcare

Associated Press

17-03-2025

NEW YORK, March 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ('Baird Medical' or the 'Company') has been honored with the 'Most Valuable Investment Award' at the 10th China Medical Industry Innovation Competition with its revolutionary in-development product, the 'AI Tumor Ablation Surgical Robot.' This prestigious recognition marks a significant milestone in the advancement of AI and robotics integration that Baird Medical is developing in the medical field.
AI & Robotics: Redefining the Paradigm of Precision Medicine
Baird Medical's AI Tumor Ablation Surgical Robot will be an intelligent surgical system that seamlessly integrates multimodal AI algorithms with high-precision robotic arm control. Its key innovations will include:
Autonomous Decision-Making & Dynamic Optimization – Using an AI-powered real-time learning framework, the system simultaneously analyzes intraoperative imaging, physiological data, and thermal field simulations to dynamically adjust ablation parameters with millimeter-level precision.
Multi-Technology Synergy Platform – Integrating microwave, radiofrequency, laser, and nano-knife ablation technologies, the AI algorithm optimizes surgical site selection, nodule characteristics, energy output, and ablation method, overcoming the limitations of traditional single-technique approaches.
End-to-End Intelligent Automation: Leveraging AI-driven precision, the system seamlessly integrates preoperative 3D lesion segmentation, millimeter-level path planning, and intraoperative micron-level fully automated surgery, followed by predictive postoperative outcome analysis. Surgeons serve as overseers, intervening only at critical junctures in a passive mode as needed. This transformative approach will effectively enhance surgical efficiency.
As the 'brain' of the system, Baird Medical's proprietary AI-driven platform will offer three key technological advantages:
Establishing an Extensive Medical Knowledge Base – Integrates over 100,000 tumor ablation image cases and 50,000 pathology reports, enabling cross-modal data correlation and in-depth analysis.
Building a Self-Evolving Learning Architecture – Utilizes federated learning technology to enable secure data sharing across global partner hospitals, reducing model iteration cycles to just a few weeks.
Implementing Quantum-Optimized Pretraining – In future collaboration with quantum computing centers, leverages quantum optimization algorithms to overcome the computational bottlenecks of traditional deep learning, significantly accelerating inference speed.
World-Class R&D Team & Cutting-Edge Development: A Milestone in Medical Technology
This project will actively implement Baird Medical's R&D strategy of 'Global Expertise + Local Innovation,' built on three core pillars.
Building an Elite Interdisciplinary Team – Bringing together top-tier medical robotics experts from Nanyang Technological University, globally renowned oncologic surgeons, and former AI algorithm engineers from the Chinese Academy of Sciences. This core team has deep expertise in AI-driven medical applications and has collectively filed over 90 patents.
Establishing a Comprehensive Validation Framework – Implementing rigorous multi-center clinical simulations across 20 top-tier hospitals in the U.S., Europe, and China to ensure the system's safety, reliability, and efficacy in complex surgical environments.
Advancing an Ethics-Driven AI Design – Developing the world's first AI-powered surgical ethics decision module, incorporating real-time risk alerts and redundant operation validation to proactively mitigate surgical complications, with a targeted reduction to below 1%.
Expanding Applications: From Tumor Treatment to a Minimally Invasive Revolution
This cutting-edge system extends beyond the precise ablation of solid tumors such as thyroid nodules, breast nodules, liver cancer, and lung cancer—it also marks a breakthrough in chronic pain management. More notably, its modular design is expected to enable rapid adaptation for applications in neurosurgery (e.g., epilepsy lesion localization) and urology (e.g., prostate ablation).
The launch of Baird Medical's AI-powered tumor ablation robotic system represents not only a paradigm shift in the integration of AI and robotics but also a redefinition of excellence in medical innovation. By harnessing deep learning as the foundation for next-generation medical AI, the system is transforming minimally invasive surgery from an experience-based practice to a data-driven discipline. As commercial deployment expands across 30+ countries, the future of intelligent healthcare is now within reach.
The development of Baird Medical's AI-powered tumor ablation surgical robot will not only set a benchmark for the integration of AI and robotics but also redefine the standards for high-quality medical innovation. By harnessing deep learning as the foundation for next-generation medical AI, the system aims to transform minimally invasive surgery from an experience-based practice to a data-driven one. If successfully commercialized, the system is expected to initiate regulatory approvals and market expansion across more than 30 countries, bringing the future of intelligent healthcare within reach.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as 'may', 'could', 'should', 'expect', 'intend', 'might', 'will', 'estimate', 'anticipate', 'believe', 'budget', 'forecast', 'intend', 'plan', 'potential', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled 'Risk Factors' therein, and in ExcelFin's other filings with the SEC.
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact: